Effect of adding letrozole to gonadotropin on in vitro fertilization outcomes: An RCT.
Ovarian stimulation
Pregnancy.
Letrozole
Journal
International journal of reproductive biomedicine
ISSN: 2476-4108
Titre abrégé: Int J Reprod Biomed
Pays: Iran
ID NLM: 101679102
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
16
03
2019
revised:
23
10
2019
accepted:
27
11
2019
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
5
6
2020
Statut:
epublish
Résumé
Aromatase inhibitors prevent the aromatization of androgens into estrogens, which reduces the negative feedback of estrogen on the hypothalamic-pituitary axis. It is clear that increasing the secretion of follicle-stimulating hormones results in an increased follicular growth. This study aimed to evaluate the effect of adding letrozole to gonadotropin on in vitro fertilization outcomes in normal responders. In this randomized clinical trial, 100 normal responder women candidate for controlled ovarian stimulation were randomly enrolled in two groups (n = 50/each). In the case group letrozole was added to gonadotropin in the antagonist protocol. The control group received the conventional antagonist protocol. The main outcome was clinical and chemical pregnancy; and the second outcomes were the number of mature oocytes, the fertilization rate, estradiol level, and the total dose of gonadotropins. Basic clinical and demographic features were comparable between the groups. Estradiol level on the day of human-chorionic-gonadotropin administration and the total gonadotropin consumption were significantly higher in the control group than the case group (p = 0.045). In addition, the number of MII oocytes was higher (but not significantl) in the case group than the control group (p = 0.09). Moreover, the endometrial thickness was significantly lower in the case group. There were no significant differences in fertilization rate and chemical and clinical pregnancy rates between the two groups. Although adding letrozole to gonadotropin in normal responders reduces the total dose of gonadotropin, it does not improve the pregnancy outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Aromatase inhibitors prevent the aromatization of androgens into estrogens, which reduces the negative feedback of estrogen on the hypothalamic-pituitary axis. It is clear that increasing the secretion of follicle-stimulating hormones results in an increased follicular growth.
OBJECTIVE
OBJECTIVE
This study aimed to evaluate the effect of adding letrozole to gonadotropin on in vitro fertilization outcomes in normal responders.
MATERIALS AND METHODS
METHODS
In this randomized clinical trial, 100 normal responder women candidate for controlled ovarian stimulation were randomly enrolled in two groups (n = 50/each). In the case group letrozole was added to gonadotropin in the antagonist protocol. The control group received the conventional antagonist protocol. The main outcome was clinical and chemical pregnancy; and the second outcomes were the number of mature oocytes, the fertilization rate, estradiol level, and the total dose of gonadotropins.
RESULTS
RESULTS
Basic clinical and demographic features were comparable between the groups. Estradiol level on the day of human-chorionic-gonadotropin administration and the total gonadotropin consumption were significantly higher in the control group than the case group (p = 0.045). In addition, the number of MII oocytes was higher (but not significantl) in the case group than the control group (p = 0.09). Moreover, the endometrial thickness was significantly lower in the case group. There were no significant differences in fertilization rate and chemical and clinical pregnancy rates between the two groups.
CONCLUSION
CONCLUSIONS
Although adding letrozole to gonadotropin in normal responders reduces the total dose of gonadotropin, it does not improve the pregnancy outcomes.
Identifiants
pubmed: 32494767
doi: 10.18502/ijrm.v13i4.6891
pmc: PMC7218674
doi:
Types de publication
Journal Article
Langues
eng
Pagination
287-294Informations de copyright
Copyright © 2020 Eftekhar et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interests.
Références
Eur J Obstet Gynecol Reprod Biol. 2016 Aug;203:30-4
pubmed: 27236602
J Hum Reprod Sci. 2012 May;5(2):170-4
pubmed: 23162355
J Clin Endocrinol Metab. 2006 Mar;91(3):760-71
pubmed: 16384846
Fertil Steril. 2017 Oct;108(4):568-571
pubmed: 28965550
Int J Reprod Biomed (Yazd). 2017 Feb;15(2):101-108
pubmed: 28462402
Gynecol Endocrinol. 2016 Oct;32(10):823-826
pubmed: 27114051
Am J Obstet Gynecol. 2017 Jan;216(1):42.e1-42.e10
pubmed: 27555316
Int J Reprod Med. 2014;2014:581451
pubmed: 25763403
Gynecol Endocrinol. 2014 May;30(5):330-4
pubmed: 24456013
Reprod Biol Endocrinol. 2018 May 29;16(1):54
pubmed: 29843716
Hum Reprod. 2017 Mar 1;32(3):568-574
pubmed: 28122888
Gynecol Endocrinol. 2016;32(3):206-9
pubmed: 26487376
Fertil Steril. 2005 Jul;84(1):82-7
pubmed: 16009161
Thromb Res. 2008;121(6):713-26
pubmed: 17659766
Iran J Reprod Med. 2014 Nov;12(11):725-30
pubmed: 25709627
Gynecol Endocrinol. 2014 Jul;30(7):485-9
pubmed: 24592985
Taiwan J Obstet Gynecol. 2010 Sep;49(3):297-301
pubmed: 21056314
Hum Reprod. 2015 Sep;30(9):2184-9
pubmed: 26109617
Reprod Biomed Online. 2006 Aug;13(2):166-72
pubmed: 16895628
Reprod Biol Endocrinol. 2017 Aug 30;15(1):70
pubmed: 28854933